Stage IV melanoma represents the most advanced form of this skin cancer, where the disease has traveled beyond its original location to distant parts of the body. While this diagnosis brings significant challenges, recent years have witnessed remarkable progress in treatment approaches, offering patients new hope and possibilities that were unimaginable just a decade ago.

Understanding Treatment Goals When Cancer Has Spread

When melanoma reaches stage IV, it means the cancer has moved far from where it first appeared. The disease may have traveled to organs like the lungs, liver, brain, or bones, or spread to distant areas of skin and lymph nodes that are far from the original tumor. At this advanced stage, the main goals of treatment shift from trying to remove all cancer through surgery alone to controlling the disease throughout the body, managing symptoms, and maintaining the best possible quality of life for as long as possible.^[1]

Treatment decisions for stage IV melanoma depend on many factors that are unique to each person. Doctors consider where exactly the cancer has spread, how much of the body is affected, the patient’s overall health and fitness level, and what symptoms they are experiencing. The location of metastases matters greatly because melanoma that has spread to certain organs may be treated differently than when it affects other areas. For example, cancer in the lungs might be approached differently than disease in the brain or liver.^[2]

Medical guidelines from national and international cancer organizations provide frameworks for treating advanced melanoma, but these are constantly evolving as new research emerges. The landscape of melanoma treatment has changed dramatically over the past decade, with options expanding from very limited choices to a range of powerful therapies. Some treatments work by helping the immune system recognize and attack cancer cells, while others target specific molecular changes inside melanoma cells that drive their growth.^[7]

Beyond standard approved treatments, clinical trials offer access to experimental therapies that may provide additional benefits. Because the field is developing so rapidly, doctors strongly encourage patients with stage IV melanoma to consider participating in clinical research, both when first starting treatment and if the disease progresses despite initial therapy. These trials not only provide patients with access to cutting-edge approaches but also help advance medical knowledge for future patients.^[1]

Standard Treatment Approaches

Immunotherapy: Awakening the Body’s Defense System

Immunotherapy has revolutionized the treatment of advanced melanoma by helping the patient’s own immune system fight cancer. These drugs work by removing the “brakes” that cancer cells place on immune responses, allowing the body’s natural defenses to recognize and destroy melanoma cells. Several immunotherapy medications have become cornerstones of stage IV melanoma treatment, offering hope where few options existed before.^[13]

The most commonly used immunotherapy drugs belong to a class called checkpoint inhibitors. These include nivolumab, sold under the brand name Opdivo, and pembrolizumab, marketed as Keytruda. Both target a protein called PD-1 on immune cells, essentially releasing the immune system to attack cancer. These medications are given through an intravenous infusion, typically every two to four weeks depending on the specific drug and dosing schedule.^[13]

Another checkpoint inhibitor, ipilimumab (Yervoy), works differently by targeting a protein called CTLA-4. While it can be used alone, doctors sometimes combine ipilimumab with nivolumab for patients who may benefit from a more aggressive immune activation. This combination approach can produce stronger responses in some people, though it also carries a higher risk of side effects. A newer option combines nivolumab with another drug called relatlimab (together marketed as Opdualag), which targets an additional immune checkpoint to potentially enhance effectiveness.^[13]

For certain patients with melanoma that has spread to nearby skin or lymph vessels but cannot be surgically removed, localized immunotherapy may be an option. This involves injecting the treatment directly into tumors rather than giving it through the bloodstream. Aldesleukin, also known as interleukin-2 or IL-2, can be administered this way. Another localized approach uses imiquimod, a cream applied directly to the skin, sometimes combined with aldesleukin injections.^[13]

Targeted Therapy: Blocking Cancer’s Growth Signals

Targeted therapy represents another major advance in melanoma treatment. These drugs work by attacking specific molecular abnormalities inside cancer cells that drive their uncontrolled growth. However, targeted therapy only works for patients whose melanoma carries particular genetic mutations. About half of all melanomas have a mutation in a gene called BRAF, which makes them candidates for targeted treatment.^[13]

The most common targeted therapy approach for stage IV melanoma involves combining two drugs: a BRAF inhibitor with a MEK inhibitor. These work together to block different steps in the same growth pathway that cancer cells use to multiply. Common combinations include dabrafenib (Tafinlar) paired with trametinib (Mekinist), vemurafenib (Zelboraf) combined with cobimetinib (Cotellic), and encorafenib (Braftovi) used with binimetinib (Mektovi). All of these are pills taken by mouth daily, making them more convenient than intravenous treatments.^[13]

One advantage of targeted therapy is that it often works very quickly, sometimes shrinking tumors within weeks. This rapid response can be especially valuable for patients who need fast symptom relief. However, a limitation is that cancer cells can eventually develop resistance to these drugs, often after several months or years of treatment. How long the medication remains effective varies greatly from person to person.^[13]

Before starting targeted therapy, patients must have their tumor tested to confirm the presence of a BRAF mutation. Some patients with different genetic abnormalities, such as mutations in the C-KIT gene, may be candidates for other targeted drugs like imatinib (Gleevec). Genetic testing of the tumor helps doctors identify which patients are most likely to benefit from targeted approaches.^[13]

Side effects of targeted therapy differ from those of immunotherapy. Common problems include fever, chills, fatigue, joint pain, skin rash, and sensitivity to sunlight. Some patients develop changes in their skin or experience nausea and diarrhea. Heart rhythm abnormalities and eye problems can occur, so regular monitoring throughout treatment is essential. Most side effects can be managed by adjusting the dose or temporarily stopping treatment.

Surgery in Advanced Disease

While surgery is not typically the primary treatment for stage IV melanoma, it can play a role in carefully selected situations. If cancer has spread to only one or a few locations that are accessible, removing those metastases surgically might help control the disease, especially when combined with other treatments. For example, if melanoma has spread to a single spot in the lung, liver, brain, or intestine, doctors might recommend surgery to remove that area.^[2]

Surgery might also be appropriate when cancer has spread to a limited number of lymph node groups or to small areas on or just under the skin. The goal in these cases is to reduce the amount of disease in the body, potentially making other treatments more effective. However, surgery alone is rarely sufficient for stage IV melanoma, and patients typically receive additional systemic therapy like immunotherapy or targeted drugs.^[13]

Radiation Therapy for Symptom Control

Radiation therapy uses high-energy rays to destroy cancer cells in specific locations. For stage IV melanoma, radiation is most commonly used to relieve symptoms caused by metastases rather than to cure the disease. It can be particularly helpful for melanoma that has spread to the brain or bones, where tumors may cause pain, neurological symptoms, or risk of fracture.^[2]

When melanoma spreads to the brain, radiation to these metastases can help prevent or reduce symptoms like headaches, seizures, weakness, or confusion. Similarly, radiation to bone metastases can effectively control pain and reduce the risk of bones breaking. The treatment is typically given over several sessions, though sometimes a single high dose can be delivered using specialized techniques.

Chemotherapy: A Less Common Option

Traditional chemotherapy has largely been replaced by immunotherapy and targeted therapy as the preferred treatments for stage IV melanoma. These newer approaches generally work better and cause fewer severe side effects. However, chemotherapy may still be used in certain situations, particularly for patients who cannot receive or have not responded to immunotherapy or targeted drugs.^[2]

Dacarbazine remains the most commonly used chemotherapy drug for melanoma when this approach is needed. It was approved decades ago and was long considered the standard of care before newer treatments became available. Response rates to single-agent chemotherapy are generally modest, ranging from 5% to 20%, and responses are usually temporary.^[10][12]

Specialized chemotherapy approaches may be used for melanoma confined to an arm or leg. Isolated limb perfusion or isolated limb infusion involves delivering high doses of chemotherapy medication directly to the affected limb while temporarily isolating its blood supply from the rest of the body. This allows much higher drug concentrations to reach the tumors while limiting exposure to the rest of the body. Another technique called electrochemotherapy combines chemotherapy with brief electrical pulses that help the drugs enter cancer cells more effectively.^[2]

Promising Treatments in Clinical Trials

The rapid pace of melanoma research means that numerous experimental therapies are constantly being evaluated in clinical trials. These investigations span all phases of development, from early safety testing to large comparison studies against standard treatments. Patients with stage IV melanoma have many opportunities to access these novel approaches through trial participation.^[7]

Next-Generation Immunotherapies

Researchers are developing new immunotherapy approaches that work through different mechanisms than current checkpoint inhibitors. Some experimental drugs target additional immune checkpoints beyond PD-1 and CTLA-4, potentially offering options for patients whose disease progresses on existing treatments. Other strategies focus on stimulating specific parts of the immune response more precisely.

Cancer vaccines represent an exciting area of clinical investigation. Unlike vaccines that prevent infectious diseases, therapeutic cancer vaccines are designed to train the immune system to recognize and attack existing tumors. These vaccines contain melanoma-associated proteins or genetic material that helps the immune system learn to target cancer cells more effectively. Multiple vaccine approaches are being tested in clinical trials at various medical centers.

Adoptive cell therapy involves collecting a patient’s own immune cells, modifying or expanding them in the laboratory, then returning them to the patient to fight cancer. Tumor-infiltrating lymphocyte (TIL) therapy is one such approach that has shown promising results in melanoma trials. Doctors remove immune cells that have already penetrated the tumor, grow large numbers of them outside the body, then infuse them back into the patient along with immune-stimulating factors. This treatment requires specialized centers with expertise in cellular therapies.

Novel Targeted Therapies

Beyond BRAF and MEK inhibitors, scientists are developing targeted drugs against other molecular abnormalities found in melanoma cells. Research focuses on identifying additional genetic mutations and biological pathways that drive cancer growth, then designing drugs to block these specifically. Some experimental targeted therapies work against proteins involved in cell division, DNA repair, or other critical cancer cell functions.

Combination approaches that pair targeted therapy with immunotherapy are also under investigation. The rationale is that targeted drugs might make tumors more visible to the immune system, potentially enhancing the effectiveness of immunotherapy. Several clinical trials are testing whether combining these treatment types produces better outcomes than using either alone.

Oncolytic Virus Therapy

Talimogene laherparepvec (T-VEC) is a genetically modified virus approved for treating melanoma that cannot be surgically removed when it has spread to the skin or lymph nodes. The virus is injected directly into tumors, where it multiplies inside cancer cells, causing them to burst open and die. This releases tumor antigens that can alert the immune system to attack melanoma cells elsewhere in the body.^[2]

While T-VEC itself is already approved, researchers continue investigating oncolytic virus approaches. Studies are examining whether combining viral therapy with checkpoint inhibitors produces better results than either treatment alone. Additional virus types are also being engineered and tested in early phase trials.

Understanding Clinical Trial Phases

Clinical trials progress through distinct phases, each designed to answer specific questions about a new treatment. Phase I trials primarily focus on safety, determining what doses can be given without causing unacceptable side effects. These studies typically enroll small numbers of patients and represent the first testing of a treatment in humans.^[7]

Phase II trials examine whether the treatment shows signs of effectiveness against cancer. These studies enroll more patients and carefully measure response rates and other indicators that the treatment is working. Phase II trials also continue gathering safety information across larger groups of people.

Phase III trials are large comparison studies that test whether a new treatment performs better than the current standard of care. These trials randomly assign patients to receive either the experimental therapy or standard treatment, then compare outcomes between groups. Positive Phase III results are typically required for regulatory approval of new treatments.

Finding and Joining Clinical Trials

Clinical trials for melanoma are conducted at cancer centers throughout the United States, Europe, and other regions worldwide. Major academic medical centers and specialized cancer hospitals typically offer the most trial options. Some trials have specific eligibility requirements regarding where the cancer has spread, what previous treatments the patient has received, overall health status, and other factors.^[7]

Patients interested in clinical trials can discuss options with their oncologist, who can help identify appropriate studies. Online databases maintained by government agencies and cancer organizations allow searching for trials by disease type and location. Some patients seek second opinions at major cancer centers specifically to explore trial opportunities not available at their local hospital.

Most Common Treatment Methods

• Immunotherapy
  • Checkpoint inhibitors like nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) that remove immune system brakes
  • Combination immunotherapy using nivolumab plus ipilimumab or nivolumab plus relatlimab (Opdualag)
  • Localized immunotherapy including aldesleukin (interleukin-2) injected into tumors
  • Topical imiquimod cream applied to skin metastases
• Targeted Therapy
  • BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) combined with MEK inhibitors (trametinib, cobimetinib, binimetinib)
  • Imatinib (Gleevec) for melanomas with C-KIT mutations
  • All targeted therapies taken as daily pills by mouth
• Surgery
  • Removal of limited metastases in the lung, liver, brain, or intestine when feasible
  • Excision of skin or lymph node metastases in selected cases
  • Usually combined with systemic therapy rather than used alone
• Radiation Therapy
  • Treatment of brain metastases to control symptoms and prevent complications
  • Radiation to bone metastases for pain relief and fracture prevention
  • Focused radiation to other symptomatic metastases
• Oncolytic Virus Therapy
  • Talimogene laherparepvec (T-VEC) injected directly into skin or lymph node metastases
  • Genetically modified virus that kills cancer cells and stimulates immune response
• Specialized Regional Therapy
  • Isolated limb perfusion delivering high-dose chemotherapy to an affected arm or leg
  • Isolated limb infusion as a less invasive alternative
  • Electrochemotherapy combining chemotherapy with electrical pulses
• Chemotherapy
  • Dacarbazine given intravenously, primarily when other options are not suitable
  • Generally reserved for patients unable to receive immunotherapy or targeted therapy
  • Response rates of 5% to 20% with temporary tumor shrinkage